2019-001493-28: Raxone® treatment for patients with autosomal dominant optic atrophy (inherited optic nerve disorder) Raxone® Behandlung bei Patienten mit autosomal dominanter Optikusatrophie (erblich bedingte Erkrankung des Sehnerves). |
|
|
| Ongoing | 2 | 16 | Europe | Raxone 150 mg film-coated tablets, Film-coated tablet, Raxone 150 mg film-coated tablets | Medizinische Universität Graz, Univ.-Augenklinik, Chiesi Pharmaceuticals GmbH | Autosomal dominant optic atrophy (ADOA) Autosomal dominante Optikusatrophie, inherited disorder of the optic nerve erblich bedingte Erkrankung des Sehnervs, Diseases [C] - Eye Diseases [C11] | | | | |
US EAP LHON, NCT04381091: Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study |
|
|
| No Longer Available | N/A | | NA | Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Leber's Hereditary Optic Neuropathy | | | | |